Health care stocks were steady premarket Friday, with The Health Care Select Sector SPDR Fund (XLV) marginally higher and the iShares Biotechnology ETF (IBB) inactive.
BeiGene (BGNE) shares were up over 2% after the company said overnight it signed a global licensing deal with CSPC Zhongqi Pharmaceutical Technology for its experimental cancer therapy, SYH2039.
Geron (GERN) stock was over 1% higher after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Rytelo for the treatment of adult patients with transfusion-dependent anemia due to lower risk myelodysplastic syndromes.
Candel Therapeutics (CADL) shares were down past 33% after the company said overnight it priced an underwritten public offering of 10 million common shares at $6 apiece and pre-funded warrants to buy up to a total of 3.3 million shares of its common stock at $5.99 per warrant to raise about $80 million in gross proceeds.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。